Showing results (121-130 of 155) with videos related to

Sort By:
Pageof 16
Annals of Hematology|June 19, 2013
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAli T Taher, John B Porter, Vip Viprakasit, et al.
American Journal of Hematology|November 6, 2018
Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO© )Ali Taher, Maria Domenica Cappellini, Vip Viprakasit, et al.
American Journal of Hematology|September 24, 2017
Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemiaAli T Taher, Antoine N Saliba, Kevin H Kuo, et al.
Blood|April 16, 2005
Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportinHal Drakesmith, Lisa M Schimanski, Emma Ormerod, et al.
BMJ Open|March 22, 2023
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemiaAli T Taher, Khaled M Musallam, Vip Viprakasit, et al.
American Journal of Hematology|November 6, 2018
Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO© )Ali Taher, Vip Viprakasit, Maria Domenica Cappellini, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 5, 2009
Adventitious changes in long-range gene expression caused by polymorphic structural variation and promoter competitionKaren M Lower, Jim R Hughes, Marco De Gobbi, et al.
BMJ Open|November 14, 2024
Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trialAli T Taher, Khaled M Musallam, Vip Viprakasit, et al.
The Lancet. Haematology|August 21, 2022
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trialAndreas Glenthøj, Eduard J van Beers, Hanny Al-Samkari, et al.
Blood|January 19, 2012
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overloadEllis J Neufeld, Renzo Galanello, Vip Viprakasit, et al.
Pageof 16